| Role |
Name |
Disclosure |
Details |
| Author | Samuel T Olatunbosun, MD, Chief, Internal Medicine, 56th Medical Group, Luke Air Force Base | Nothing to disclose | Details | | Coauthor | Samuel Dagogo-Jack, MD, MBBS, MSc, FRCP, Professor of Medicine, Program Director, Division of Endocrinology, Diabetes and Metabolism, University of Tennessee Health Science Center | Eli Lilly GlaxoSmithKline Merck | Details | | Medical Editor | David S Schade, MD, Chief, Division of Endocrinology and Metabolism, Department of Internal Medicine, Professor, University of New Mexico School of Medicine and Health Sciences Center | Nothing to disclose | Details | | Pharmacy Editor | Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine | Nothing to disclose | Details | | Managing Editor | Don S Schalch, MD, Professor Emeritus, Department of Internal Medicine, Division of Endocrinology, University of Wisconsin Hospitals and Clinics | Nothing to disclose | Details | | CME Editor | Mark Cooper, MBBS, PhD, FRACP, Head, Diabetes & Metabolism Division, Baker Heart Research Institute, Professor of Medicine, Monash University | Nothing to disclose | Details | | Chief Editor | George T Griffing, MD, Professor of Medicine, St Louis University School of Medicine | Nothing to disclose | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| David S Schade, Medical Editor |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Don S Schalch, Managing Editor |
The contributor discloses no conflict of interest. |
|